The FDA approved Eli Lilly and Co.’s Taltz (ixekizumab) injection 80 mg/mL for the treatment of adults with active ankylosing spondylitis, also known as radiographic axial spondyloarthritis.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00PR Newswirehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngPR Newswire2019-08-26 06:45:372019-08-26 13:20:32Lilly Receives U.S. FDA Approval for Taltz for the Treatment of Active Ankylosing Spondylitis
